[8-K] Standard BioTools Inc. Reports Material Event

Rhea-AI Filing Summary

Standard BioTools Inc. (LAB) furnished a Current Report on Form 8-K stating it issued a press release dated August 11, 2025 that includes information about certain financial results for the three and six months ended June 30, 2025. The press release is attached as Exhibit 99.1.

The filing specifies that the press release content, excluding the sections titled "Full Year 2025 Revenue Outlook" and "About Standard BioTools Inc." together with the forward-looking statement disclaimer, is incorporated by reference into Item 2.02, while those excluded sections and the disclaimer are incorporated by reference into Item 7.01. The report is furnished, not filed, and is signed by Alex Kim, Chief Financial Officer.

Insights

Securities Analyst

TL;DR: Routine 8-K furnishes Q2 financial results via attached press release; the filing itself contains no numeric results.

The Form 8-K states Standard BioTools issued a press release dated August 11, 2025 that includes information for the three and six months ended June 30, 2025 and attaches it as Exhibit 99.1. The filing does not reproduce the financial figures; it instead incorporates most of the press release by reference. The submission is explicitly furnished (not filed), which limits Section 18 liability for the disclosed material.

Corporate Governance Expert

TL;DR: Procedural disclosure; the company clearly delineates which press release sections are incorporated and confirms officer-level signing.

The 8-K identifies which portions of the attached press release are incorporated into Item 2.02 and Item 7.01 and notes the forward-looking statement disclaimer treatment. The document is signed by the CFO, indicating internal authorization for the disclosure. The filing contains no disclosures of leadership changes, material transactions, or governance actions.

8-K Event Classification

3 items: 2.02, 7.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Accepted by SEC EDGAR 08/11/2025 - 05:00 PM Learn about SEC filing dates

false000116219400011621942025-08-112025-08-11

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): August 11, 2025

Standard BioTools Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation or organization)	001-34180 (Commission File Number)	77-0513190 (I.R.S. Employer Identification Number)
2 Tower Place, Suite 2000 South San Francisco, California 94080
(Address of principal executive offices and zip code)
(650) 266-6000
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class		Trading Symbol		Name of each exchange on which registered
Common stock, $0.001 par value per share		LAB		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 12b-2 of the Exchange Act.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 - Results of Operations and Financial Condition

On August 11, 2025, Standard BioTools Inc. issued a press release which included information with respect to certain financial results for the three and six months ended June 30, 2025. The press release is attached hereto as Exhibit 99.1.

The information set forth in the press release, except for the information set forth under the heading “Full Year 2025 Revenue Outlook” and under the heading “About Standard BioTools Inc.,” together with the forward-looking statement disclaimer, is incorporated by reference into this Item 2.02 of this Current Report on Form 8-K.

Item 7.01. Regulation FD Disclosure.

The information set forth under the heading “Full Year 2025 Revenue Outlook” and under the heading “About Standard BioTools Inc.,” together with the forward-looking statement disclaimer, is incorporated by reference into this Item 7.01 of this Current Report on Form 8-K.

Item 9.01 - Financial Statements and Exhibits

(d) Exhibits

Exhibit No.		Description
99.1		Press release issued by Standard BioTools Inc., dated August 11, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

The information in Item 2.02 and Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Date:		August 11, 2025
	STANDARD BIOTOOLS INC.
	By:		/s/ Alex Kim
	Name:		Alex Kim
	Title:		Chief Financial Officer
			(Principal Financial and Accounting Officer)